Massachusetts Financial Services Co. MA Has $105.95 Million Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Massachusetts Financial Services Co. MA cut its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 0.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,003,066 shares of the medical equipment provider's stock after selling 3,151 shares during the period. Massachusetts Financial Services Co. MA owned approximately 0.50% of Zimmer Biomet worth $105,954,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Dunhill Financial LLC grew its position in shares of Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider's stock valued at $26,000 after purchasing an additional 218 shares during the last quarter. Stonebridge Financial Group LLC acquired a new stake in Zimmer Biomet in the 4th quarter valued at approximately $25,000. Kentucky Trust Co bought a new position in Zimmer Biomet in the 4th quarter worth approximately $39,000. OFI Invest Asset Management acquired a new position in shares of Zimmer Biomet during the fourth quarter worth approximately $40,000. Finally, SRS Capital Advisors Inc. boosted its position in shares of Zimmer Biomet by 146.9% in the fourth quarter. SRS Capital Advisors Inc. now owns 479 shares of the medical equipment provider's stock valued at $51,000 after acquiring an additional 285 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently commented on ZBH. Needham & Company LLC restated a "hold" rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Royal Bank of Canada reduced their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, February 7th. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a "neutral" rating to an "overweight" rating and lifted their target price for the company from $125.00 to $128.00 in a research report on Tuesday, December 17th. JMP Securities reissued a "market outperform" rating and issued a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Truist Financial reaffirmed a "hold" rating and set a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $124.15.

Remove Ads

Zimmer Biomet Stock Down 2.3 %

Shares of NYSE ZBH traded down $2.38 during mid-day trading on Thursday, reaching $101.06. 914,715 shares of the company's stock were exchanged, compared to its average volume of 1,613,011. Zimmer Biomet Holdings, Inc. has a twelve month low of $97.69 and a twelve month high of $128.55. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The business has a fifty day simple moving average of $106.54 and a 200 day simple moving average of $107.10. The firm has a market capitalization of $20.12 billion, a price-to-earnings ratio of 22.69, a PEG ratio of 1.95 and a beta of 0.84.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period last year, the business earned $2.20 EPS. As a group, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.95%. The ex-dividend date is Monday, March 31st. Zimmer Biomet's dividend payout ratio (DPR) is currently 21.57%.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This represents a 14.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.95% of the stock is owned by insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.